BioXcel Q1 net loss narrows to $26.8M on IGALMI revenue growth of 182% YoY

BioXcel Therapeutics, Inc.

2024-Q1 EPS reported -$0.87 revenue$582,000

IGALMI net revenue $582K (Q1 2024), up 182% YoY and 55% sequentially.
Net loss of $26.8M vs $52.8M in Q1 2023; operating cash used $17.7M.
Cash $74.1M at March 31, 2024, including $25M from March direct offering.
Advanced two Phase 3 trials for BXCL501: TRANQUILITY In-Care (60 mcg) for Alzheimer's agitation and SERENITY At-Home (120 mcg) for bipolar/schizophrenia; FDA protocol submitted.
Two new patents granted for BXCL501 (Japan and U.S.) extending protection to 2039/2043.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BioXcel Therapeutics, Inc. reported first quarter of 2024 results: revenue $582,000, net income $26.8 million.

Period: first quarter of 2024
Revenue: $582,000
Net income: $26.8 million
Result: reported results

Exact text from the filing

of BXCL701 and KEYTRUDA® (pembrolizumab) in metastatic pancreatic ductal adenocarcinoma (PDAC). First Quarter 2024 Financial Results Net Revenue: Net revenue from IGALMI was $582,000 for the first quarter of 2024, compared to $206,000 for the same period in 2023, representing a 182% increase. Sequential quarterly revenue increased 55% in Q1 2024 from the

View on SEC.gov

1443 earnings releases filed in the last 30 days. Browse all earnings releases →

BioXcel Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-059106

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.